These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20133265)

  • 1. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s).
    Clifford DB; Evans S; Yang Y; Acosta EP; Ribaudo H; Gulick RM;
    HIV Clin Trials; 2009; 10(6):343-55. PubMed ID: 20133265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study.
    Xu L; Peng W; Song X; Li Y; Han Y; Zhu T; Fu Q; Du X; Cao W; Li T
    BMC Infect Dis; 2021 Jan; 21(1):112. PubMed ID: 33485301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychological changes in efavirenz switch regimens.
    Li Y; Wang Z; Cheng Y; Becker JT; Martin E; Levine A; Rubin LH; Sacktor N; Ragin A; Ho K
    AIDS; 2019 Jul; 33(8):1307-1314. PubMed ID: 30932965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability of central nervous system symptoms among HIV-1 infected efavirenz users: analysis of patient electronic medical record data.
    Rosenblatt L; Broder MS; Bentley TGK; Chang E; Reddy SR; Papoyan E; Myers J
    AIDS Care; 2017 Aug; 29(8):1067-1073. PubMed ID: 28147708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.
    Waters L; Fisher M; Winston A; Higgs C; Hadley W; Garvey L; Mandalia S; Perry N; Nicola M; Nelson M
    AIDS; 2011 Jan; 25(1):65-71. PubMed ID: 21099666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
    Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals.
    Clifford DB; Evans S; Yang Y; Acosta EP; Goodkin K; Tashima K; Simpson D; Dorfman D; Ribaudo H; Gulick RM
    Ann Intern Med; 2005 Nov; 143(10):714-21. PubMed ID: 16287792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults.
    Takuva S; Evans D; Zuma K; Okello V; Louwagie G
    Pan Afr Med J; 2013; 15():5. PubMed ID: 23847702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study.
    Mwesigire DM; Wu AW; Martin F; Katamba A; Seeley J
    BMC Health Serv Res; 2015 Jul; 15():292. PubMed ID: 26216221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV.
    Xia H; Huang XJ; Hu Y; Gao LY; Wu Y; Wu H; Yan ZF; Ma P
    Chin Med J (Engl); 2021 Oct; 134(23):2850-2856. PubMed ID: 34653085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
    Behrens G; Rijnders B; Nelson M; Orkin C; Cohen C; Mills A; Elion RA; Vanveggel S; Stevens M; Rimsky L; Thorpe D; Bosse M; White K; Zhong L; DeMorin J; Chuck SK
    AIDS Patient Care STDS; 2014 Apr; 28(4):168-75. PubMed ID: 24660840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients.
    Hawkins T; Geist C; Young B; Giblin A; Mercier RC; Thornton K; Haubrich R
    HIV Clin Trials; 2005; 6(4):187-96. PubMed ID: 16214735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D.
    Brown TT; McComsey GA
    Antivir Ther; 2010; 15(3):425-9. PubMed ID: 20516561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
    Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
    PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efavirenz is related to neuropsychiatric symptoms among adults, but not among adolescents living with human immunodeficiency virus in Kilimanjaro, Tanzania.
    Sumari-de Boer M; Schellekens A; Duinmaijer A; Lalashowi JM; Swai HJ; de Mast Q; van der Ven A; Kinabo G
    Trop Med Int Health; 2018 Feb; 23(2):164-172. PubMed ID: 29220120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
    AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depression is associated with efavirenz-containing treatments in newly antiretroviral therapy initiated HIV patients in Ecuador.
    Checa A; Castillo A; Camacho M; Tapia W; Hernandez I; Teran E
    AIDS Res Ther; 2020 Jul; 17(1):47. PubMed ID: 32727488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of Depression and Anxiety After Discontinuation of Long- Term Efavirenz Treatment.
    Mothapo KM; Schellekens A; van Crevel R; Keuter M; Grintjes-Huisman K; Koopmans P; van der Ven A
    CNS Neurol Disord Drug Targets; 2015; 14(6):811-8. PubMed ID: 25808896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-nucleoside reverse transcriptase inhibitor levels among HIV-exposed uninfected infants at the time of HIV PCR testing - findings from a tertiary healthcare facility in Pretoria, South Africa.
    Mazanderani AH; Murray TY; Sherman GG; Snyman T; George J; Avenant T; Goga AE; Pepper MS; du Plessis N
    J Int AIDS Soc; 2019 Jun; 22(6):e25284. PubMed ID: 31215757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.